Ucb Biopharma Sprl

Ucbbiopharma Srl

Harvard College

Ucb Pharma, S.a.

Biogen Idec Ma Inc.

Oxford University Innovation Ltd

Isis Innovation Limited

Biogen Ma Inc.

Kerry Louise Tyson

Helene Margaret Finney

Daniel John Lightwood

Ralph Adams

Stephen Edward Rapecki

Michael John Wright

Bryan John Smith

Alastair David Griffiths Lawson

Lara Kevorkian

Terence Seward Baker

Patrick Downey

Kaushik Sarkar

Paul Alan Atherfold

Carl Brendan Doyle

Andrew George Popplewell

David Edward Ormonde Knight

Karine Jeannine Madeleine Hervé

Ellen A Garber

Yen-Ming Hsu

Linda C Burkly

Frederick Robbins Taylor

Martyn Kim Robinson

Derek Thomas Brown

David James McMillan

Stevan Graham Shaw

Lihe Su

Georges Mairet-Coello

Jean-Philippe Courade

Gökhan S Hotamisligil

Shauna Mhairi Wales

Christoph Meier

Joanne Elizabeth Compson

Elisabeth Helen Roberts

Andrew Charles Payne

Mehmet F Burak

Feyza Engin

Scott B Widenmaier

Neil Gozzard

Roger Thomas Palframan

Lorenzo De Lichtervelde

Adrian Richard Moore

Janine L Ferrant-Orgettas

Anthony Shock

Simon Paul Davis

Mark Ellis

Thomas Allen Ceska

Diane Marshall

Alison Turner

Karen Inouye

Peter Charles Elliott

Helene Bon

Kate Louise Dixon

Maria Margarida Gouveia Sancho

Raymond Anthony Jupp

Joseph Michael David Rastrick

Monika-Sarah Schulze

Marco Kriek

Alastair David Lawson

David Paul Humphreys

Jonathan Alexander Terrett

Alasdair Stamps

Edward Alexander McKenzie

Matthew Jon Timothy Page

Nicola Louise Fisher

Brendon Mackenzie

Matthew Cox

David Edward Knight

Georges Mairet- Coello

Karine Jeannine Madeleine HervÉ

The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

Anti-alpha-synuclein antibodies

The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

Anti-FcRn antibodies

The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

Antibody molecules which bind CD22

This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as 'aP2') for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.

Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders

The present invention relates to Tau-binding antibodies and binding fragments thereof.

Tau-binding antibodies

The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.

Antibody molecules which bind CD45

The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.

Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis

Anti-alpha synuclein antibodies

The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.

Molecules with specificity for CD79 and CD22

Antibodies specific to FCRN

Growing community of inventors

Slough, United Kingdom

Kerry Louise Tyson